BTBD4 Activators
The activators of BTBD4 comprise a diverse array of chemical compounds that indirectly amplify BTBD4's functional activity through distinct signaling pathways. Forskolin and IBMX, by increasing cAMP levels, work to activate PKA, which could lead to enhanced BTBD4 activity as PKA phosphorylates proteins that may interact with BTBD4. The calcium ionophore A23187 raises intracellular calcium, triggering calcium-dependent kinases that could phosphorylate BTBD4-associated proteins. Similarly, PMA, a PKC activator, may initiate phosphorylation cascades that bolster BTBD4's role in cellular mechanisms. Epigallocatechin Gallate and the PI3K inhibitors LY294002 and Wortmannin could indirectly potentiate BTBD4's pathway by inhibiting kinases that are upstream or competitive, thus reducing interference with BTBD4's functional pathway.
Sphingosine-1-phosphate and Genistein modulate sphingolipid and tyrosine kinase signaling, respectively, potentially augmenting signaling pathways that engage BTBD4 by reducing competitive phosphorylation events. The inhibition of p38 MAPK by SB203580 may reroute signaling to favor BTBD4 pathway activation. Similarly, U0126's suppression of MEK1/2 can lead to the preferential activation of BTBD4-involved pathways. Lastly, Staurosporine, despite being a broad-spectrum kinase inhibitor, might enable the selective activation of pathways associated with BTBD4 by alleviating specific kinase-mediated negative regulation. Theseactivators, through their targeted biochemical actions, ensure that BTBD4's functional capacity is enhanced by manipulating the signaling milieu to favor pathways where BTBD4 operates, without necessitating a direct increase in its expression or direct activation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin increases intracellular cAMP levels, which can activate PKA. PKA then phosphorylates specific proteins that can interact with BTBD4, leading to its enhanced functional activity in cellular processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
IBMX inhibits phosphodiesterases, leading to increased cAMP levels in the cell, similarly activating PKA and potentially enhancing the functional interaction with BTBD4. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels, which can activate calcium-dependent protein kinases. These kinases could phosphorylate substrates or cofactors associated with BTBD4, thus enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a potent PKC activator. PKC activation can lead to downstream signaling events that include phosphorylation of molecules within the pathway where BTBD4 is active, enhancing its functional role. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
This compound acts as a kinase inhibitor, potentially reducing the phosphorylation of proteins that compete with or negatively regulate BTBD4, thereby enhancing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it can reduce competitive signaling pathways and thus indirectly enhance pathways where BTBD4 is involved by reducing negative regulation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor with a similar function to LY294002, potentially enhancing BTBD4 activity by altering the signaling landscape in favor of pathways associated with BTBD4. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
This compound modulates sphingolipid signaling, which can lead to the activation of G-protein coupled receptors and downstream kinases that may enhance BTBD4's activity within its specific pathway. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor. It may enhance BTBD4 activity by decreasing competitive phosphorylation events and allowing for the preferential activation of pathways involving BTBD4. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38, it may shift signaling towards other pathways that include BTBD4, resulting in its enhanced activity. | ||||||